English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose of the study ENF was the first HIV entry-inhibitor approved by the FDA in 2003, which offered hope to many pretreated pts on a failing antiretroviral (ARV) regimen; but ENF is difficult to take since it requires reconstitution, parenteral administration and it causes local reactions at injection sites. Raltegravir (RAL) is the first commercially available HIV-integrase inhibitor; BENCHMARK 1–2 studies demonstrated its efficacy in treatment-experienced pts harbouring multiresistant HIV strains especially when associated with ENF in ENF-naive pts. The aim of this analysis was to longitudinally evaluate the viro-immunological and safety outcome of experienced patients switching from ENF to RAL in order to simplify the treatment schedule which may be often very complicated in 'salvage' therapy.

Switch from enfuvirtide (ENF) to raltegravir (RAL): a simplification option for heavily pretreated HIV patients (pts)